Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Launched by KYOWA KIRIN, INC. · Jul 9, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a treatment called mogamulizumab in patients with certain types of blood cancers, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). The researchers want to understand how this treatment affects patients after they have undergone a specific type of stem cell transplant known as allogeneic hematopoietic stem cell transplantation (alloHCT). The study will look at any serious health issues or side effects that may occur in these patients from January 2012 onward.

To be eligible for this study, participants must be adults aged 18 or older who have been treated for CTCL or ATLL and have received an alloHCT since January 2012. They also need to be registered with the Center for International Blood and Marrow Transplant Research (CIBMTR) and must agree to take part in the study. Participants can expect to share their medical information and any health changes they experience while being monitored for safety. It's important to note that this trial is currently recruiting new participants, so there may be an opportunity for eligible patients to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
• • Adults ≥18 years of age with either CTCL or ATLL;
• • AlloHCT performed from January 2012 onward.
• Exclusion Criteria:
• • • Patients without consent for research.